Paraganglioma and phaeochromocytoma: from genetics to personalized medicine

J Favier, L Amar, AP Gimenez-Roqueplo - Nature Reviews …, 2015 - nature.com
Paragangliomas and phaeochromocytomas are neuroendocrine tumours whose
pathogenesis and progression are very strongly influenced by genetics. A germline mutation …

Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine

S Nölting, M Ullrich, J Pietzsch, CG Ziegler… - Cancers, 2019 - mdpi.com
Pheochromocytomas and paragangliomas (PCC/PGLs) are rare, mostly catecholamine-
producing neuroendocrine tumors of the adrenal gland (PCCs) or the extra-adrenal …

Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment

VL Martucci, K Pacak - Current problems in cancer, 2014 - Elsevier
Pheochromocytomas (PHEOs) are rare neuroendocrine tumors that arise from the
chromaffin cells of the adrenal glands. Paragangliomas (PGLs), the extra-adrenal …

[HTML][HTML] mTOR pathway in colorectal cancer: an update

MG Francipane, E Lagasse - Oncotarget, 2014 - ncbi.nlm.nih.gov
The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug
development, particularly due to the fact that it plays such a crucial role in cancer biology. In …

The PI3K/Akt pathway in tumors of endocrine tissues

HL Robbins, A Hague - Frontiers in endocrinology, 2016 - frontiersin.org
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogenesis.
Defects in this pathway in human cancer syndromes such as Cowden's disease and Multiple …

Pheochromocytomas and paragangliomas

SG Tevosian, HK Ghayee - Endocrinology and Metabolism …, 2019 - endo.theclinics.com
Pheochromocytomas (PCCs) are rare neuroendocrine tumors. About 80% to 85% of these
cancers arise from chromaffin cells residing in the adrenal medulla. The remaining 15% to …

Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma

Y Pang, Y Lu, V Caisova, Y Liu, P Bullova… - Clinical Cancer …, 2018 - AACR
Purpose: Cluster I pheochromocytomas and paragangliomas (PCPGs) tend to develop
malignant transformation, tumor recurrence, and multiplicity. Transcriptomic profiling …

[HTML][HTML] Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma …

B Calsina, LJ Castro-Vega, R Torres-Pérez… - Theranostics, 2019 - ncbi.nlm.nih.gov
Abstract Rationale: Pheochromocytomas and paragangliomas (PPGLs) are rare
neuroendocrine tumors that present variable outcomes. To date, no effective therapies or …

Metastatic phaeochromocytoma: spinning towards more promising treatment options

S Nölting, A Grossman, K Pacak - Experimental and Clinical …, 2019 - thieme-connect.com
Phaeochromocytomas (PCC) and paragangliomas (PGL) are rare tumours arising from the
chromaffin cells of the adrenal medulla (PCC) or the paraganglia located outside the …

Recent advances in the management of pheochromocytoma and paraganglioma

A Tanabe, M Naruse - Hypertension Research, 2020 - nature.com
Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that cause refractory
hypertension and hypertensive crisis. Although metastatic disease accounts for 30% of …